Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Hyperfine, Inc.NASDAQ: HYPR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $3.85M fell 23.7% year over year, ahead of the -26.0% change in trailing-twelve-month research & development. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at -14.7% a year.

Context

  • Research & development amounted to 128.7% of revenue in FY2025, down 45.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -23.7% holds above the trailing-twelve-month pace of -26.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.85M+0.5% QoQ
Last fiscal yearDec 2025
$17.45M-22.4% YoY
LTMMar 2026
$16.26M-26.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.7%——
1 year-22.4%——
3-year CAGR-14.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
17.45M USD
Year-over-year change
-22.4%
4-year CAGR
-9.3%

Research & Development vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 research & development of $16.26M is the 6th highest of the 7 companies compared; the peer median is $19.91M.
  • Its year-over-year change of -26.0% is the lowest of 7, against a peer median of +12.6%.
  • Research & development amounts to 106.1% of revenue for HYPR, versus a peer median of 25.0%.
HYPR Competitors Peer median
Research & Development for HYPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M +29.2%-26.9%59059.4%
IMAImageneBio IncLTM Mar 2026$30.77M +23.4%-23.7%—
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
LUNGPulmonx CorporationLTM Mar 2026$19.63M +8.4%+8.2%22.2%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M +11.9%+8.6%—
HYPRHyperfine, Inc.LTM Mar 2026$16.26M -26.0%-14.7%106.1%
FONRFONAR CorporationLTM Mar 2026$1.77M +13.3%+1.8%1.7%
Peer median (excluding HYPR) $19.91M+12.6%+5.0%25.0%

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.5M6.81M11.03M12.89M13.56M
Cost of Revenue2.66M5.91M6.28M7M6.81M
Gross Profit(1.17M)907K4.76M5.89M6.75M
Gross Margin-78.0%13.3%43.1%45.7%49.8%
Research & Development25.84M28.16M22.49M22.5M17.45M
Selling, General & Admin37.86M46.63M30.38M26.62M26.39M
Operating Expenses63.7M74.78M52.87M49.12M43.84M
Depreciation & Amortization726K1.02M1.05M1.01M2.2M
EBITDA(64.13M)(72.15M)(43.18M)(39.71M)(33.37M)
EBITDA Margin-4286.4%-1058.8%-391.4%-308.1%-246.1%
Operating Income(64.87M)(73.87M)(48.12M)(43.22M)(37.09M)
Operating Margin-4336.1%-1084.2%-436.1%-335.3%-273.4%
Interest Income18K761K3.84M2.49M1.02M
Interest Expense00000
Other Income / Expenses17K710K3.88M2.5M1.51M
Income Before Tax(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Pre-Tax Margin-4335.0%-1073.7%-401.0%-315.9%-262.3%
Income Tax Expense00000
Net Income(64.83M)(73.16M)(44.24M)(40.72M)(35.57M)
Net Margin-4333.8%-1073.7%-401.0%-315.9%-262.3%
EPS (Basic)(0.92)(1.04)(0.62)(0.56)(0.43)
EPS (Diluted)(0.92)(1.04)(0.62)(0.56)(0.43)
Weighted Avg Shares70.33M70.45M71.32M72.41M94.2M
Weighted Avg Shares (Diluted)70.33M70.45M71.32M72.41M94.2M

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.